Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
Marios Georgakis, Research Group Leader and Physician at LMU Munich, Visiting Scientist at Broad Institute of MIT and Harvard University, shared on LinkedIn:
”In another win for genetically validated drug targets, a small molecule factor XI inhibitor on top of antiplatelet treatment, led to significant reductions (HR: 0.74, 95%CI: 0.65–0.84) in risk of recurrent ischemic stroke among patients with a non-cardioembolic ischemic stroke or TIA in the placebo-controlled OCEANIC-STROKE trial (12,327 patients).
As predicted by Mendelian randomization analyses several years ago, the benefit against ischemic stroke was not accompanied by an increase in risk of major bleeding, intracranial bleeding, or even minor bleeding.
This is unprecedented for an antithrombotic therapy.
Also interestingly, human genetic analyses had long supported no effects on myocardial infarction or coronary artery disease risk, which also lines up with the underwhelming available trial data in patients with acute myocardial infarction.”
Stay updated with Hemostasis Today.
-
Oct 7, 2026, 10:42Nasir K.: The Global Healthcare Community Comes Together for IPAW 2026
-
Oct 7, 2026, 09:20Maurizio Bertaina: Optimizing Anticoagulation in Temporary Mechanical Circulatory Support
-
Oct 7, 2026, 08:55Ifeanyichukwu Ifechidere: Cancer, Clotting and Bleeding – The Critical Role of Haemostasis in Oncology
-
Oct 7, 2026, 08:39Pediatric Hematology – Careers in Thrombosis and Blood Disorders – ASH Education
-
Oct 7, 2026, 07:57Edward Lee Carter: When Should Apixaban Become the Default for Acute VTE?
-
Oct 7, 2026, 07:40Annette Bowyer: Exploring New Developments in Thrombin Generation
-
Oct 7, 2026, 07:06Omid Seidizadeh: When Acquired von Willebrand Syndrome Takes Different Paths
-
Oct 7, 2026, 06:49Neeraj Songara: Can a Negative Antibody Screen Be Misleading?
-
Oct 7, 2026, 04:09James P. Crowley: Could the Microbiome Protect Us From Severe EBV Infection?